Breakthrough pain and its treatment: critical review and recommendations of IOPS (Italian Oncologic Pain Survey) expert group

Sebastiano Mercadante, Paolo Marchetti, Arturo Cuomo, Massimo Mammucari, Augusto Tommaso Caraceni

Research output: Contribution to journalArticlepeer-review

Abstract

Controversies exist about the definition and epidemiology of breakthrough cancer pain (BTcP), the pharmacological treatment options, drug dosing, and how to select the medications for BTcP among the new fentanyl products. Existing data were critically evaluated to provide recommendations by an expert group. An algorithm to diagnose BTcP should be used followed by a careful assessment. Fentanyl products provide efficacy and rapidity of action to counteract the temporal pattern of BTcP. The doses of opioids used for background pain should guide the choice of the doses of fentanyl products. The choice of fentanyl products should be based on individual clinical conditions.

Original languageEnglish
Pages (from-to)961-968
Number of pages8
JournalSupportive Care in Cancer
Volume24
Issue number2
DOIs
Publication statusPublished - Feb 1 2016

Keywords

  • Breakthrough pain
  • Fentanyl
  • Morphine
  • Opioids

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Breakthrough pain and its treatment: critical review and recommendations of IOPS (Italian Oncologic Pain Survey) expert group'. Together they form a unique fingerprint.

Cite this